NeurAxis Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy NRXS?
Source: seekingalpha
- Significant Revenue Growth: NeurAxis reported $1.6 million in revenue for Q1 2026, an 80% increase from $896,000 in Q1 2025, marking the strongest quarterly revenue performance in the company's history, highlighting the positive impact of the new CPT code.
- Improved Profitability: The gross margin for Q1 reached 86.4%, up from 84.4% in the same quarter last year, primarily due to the shift from discounted financial assistance to full reimbursement, indicating progress in the company's profitability model.
- Narrowing Operating Losses: The operating loss for Q1 was $1.7 million, with a net loss of $1.8 million; however, management anticipates that losses will gradually decrease as revenue grows, expecting quarterly losses to drop to below $1 million for the remainder of the year.
- VA Channel Order Growth: The company secured a federal supply schedule contract, and while significant orders were not expected in Q1, multiple VA facilities have already placed orders, indicating potential market demand and expansion opportunities in the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRXS
Wall Street analysts forecast NRXS stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.350
Low
8.00
Averages
8.00
High
8.00
Current: 8.350
Low
8.00
Averages
8.00
High
8.00
About NRXS
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeurAxis Q1 2026 Earnings Call Insights
- Significant Revenue Growth: NeurAxis reported $1.6 million in revenue for Q1 2026, an 80% increase from $896,000 in Q1 2025, marking the strongest quarterly revenue performance in the company's history, highlighting the positive impact of the new CPT code.
- Improved Profitability: The gross margin for Q1 reached 86.4%, up from 84.4% in the same quarter last year, primarily due to the shift from discounted financial assistance to full reimbursement, indicating progress in the company's profitability model.
- Narrowing Operating Losses: The operating loss for Q1 was $1.7 million, with a net loss of $1.8 million; however, management anticipates that losses will gradually decrease as revenue grows, expecting quarterly losses to drop to below $1 million for the remainder of the year.
- VA Channel Order Growth: The company secured a federal supply schedule contract, and while significant orders were not expected in Q1, multiple VA facilities have already placed orders, indicating potential market demand and expansion opportunities in the healthcare sector.
See More
NeurAxis Reports Q1 Revenue of $1.6M
- Revenue Performance: NeurAxis reported a Q1 revenue of $1.6 million for 2026, indicating stable growth potential in the market despite an uncertain overall economic environment.
- Cash Position: As of March 31, 2026, the company had a cash balance of $7.1 million, ensuring operational liquidity and the ability to invest in future opportunities, thereby boosting investor confidence.
- Successful Financing: The company raised an additional $2.1 million through its at-the-market equity offering and warrant exercises in April and May 2026, further enhancing financial flexibility and providing funding support for future expansion.
- Market Outlook: With ongoing optimization of its financial structure and revenue sources, NeurAxis is expected to enhance its competitiveness in the biotechnology sector, attracting more investor interest in its future developments.
See More
NeurAxis Reports 80% Revenue Growth in Q1 2026
- Significant Revenue Growth: NeurAxis reported revenues of $1.6 million for Q1 2026, an 80% increase year-over-year, primarily driven by the effective AMA Category I CPT® code on January 1, 2026, which substantially enhanced payer coverage and boosted sales.
- Gross Margin Improvement: The gross margin increased from 84.4% in Q1 2025 to 86.4% in Q1 2026, primarily due to a higher volume of IB-Stim® devices sold at full price, reflecting the company's strengthened competitive position in the market.
- Reduced Operating Loss: The operating loss for Q1 2026 decreased by 24% to $1.74 million, mainly due to increased gross profit from revenue growth, despite a slight rise in operating expenses driven by sales growth, indicating progress in cost control.
- Improved Cash Position: As of March 31, 2026, NeurAxis had a cash balance of $7.1 million, and subsequently raised $2.1 million through market offerings and warrant exercises in April and May 2026, further enhancing the company's liquidity and financial stability.
See More
NeurAxis Declares Dividend on Series B Preferred Stock
- Dividend Announcement: On April 10, 2026, NeurAxis announced a stock dividend for holders of Series B Preferred Stock, requiring record holders by April 21, 2026, which demonstrates the company's commitment to shareholder returns.
- Dividend Details: Each holder of Series B Preferred Stock will receive common stock based on accrued unpaid dividends at a rate of $2.38, with approximately 510,605 shares expected to be issued, enhancing the company's capital structure flexibility.
- Cash Alternative: For any fractional shares that cannot be issued, NeurAxis will compensate in cash, ensuring all shareholders receive corresponding value, reflecting the company's commitment to shareholder rights.
- Future Outlook: The dividend announcement not only indicates the company's stable financial condition but may also attract more investor interest, further boosting market confidence and potentially enhancing stock performance.
See More
Neuraxis Inc Reports Q4 2025 Earnings with Mixed Results
- Significant Revenue Growth: Neuraxis Inc reported revenues of $968,000 for Q4 2025, a 27% increase from $761,000 in Q4 2024, marking the sixth consecutive quarter of double-digit growth, indicating strong market expansion potential.
- Gross Margin Decline: Despite revenue growth, the gross margin for Q4 decreased to 85.4% from 86.4% in Q4 2024, primarily due to reserves for excess and obsolete inventory, which may impact future profitability.
- Increased Net Loss: The company reported a net loss of $1.7 million for Q4 2025, an 18% increase compared to the same period in 2024, reflecting rising operating expenses of $2.5 million, highlighting challenges in cost control.
- Strong Cash Flow Position: Neuraxis Inc ended 2025 with $5 million in cash on hand and a free cash flow of $2 million, exceeding the quarterly burn rate of $1.5 million, demonstrating robust financial management.
See More
NeurAxis Reports Q4 2025 Financial Results
- Increased Net Loss: NeurAxis reported a net loss of $1.7 million in Q4 2025, an 18% increase from $1.4 million in Q4 2024, primarily due to higher operating losses, indicating challenges in cost management.
- Revenue Performance: The revenue for the quarter stood at $0.97 million; while specific growth figures were not disclosed, the revenue level suggests insufficient competitiveness in the market, potentially impacting future financing capabilities.
- Impact of Operating Loss: The increase in operating losses puts pressure on NeurAxis's financial condition, which may lead to decreased investor confidence in the company's future profitability, thereby affecting stock performance.
- Market Reaction Expectations: Following the earnings report, market reactions to NeurAxis may lean negative, prompting investors to closely monitor how the company addresses ongoing financial challenges and its future strategic adjustments.
See More
NeurAxis Q1 2026 Earnings Call Insights
- Significant Revenue Growth: NeurAxis reported $1.6 million in revenue for Q1 2026, an 80% increase from $896,000 in Q1 2025, marking the strongest quarterly revenue performance in the company's history, highlighting the positive impact of the new CPT code.
- Improved Profitability: The gross margin for Q1 reached 86.4%, up from 84.4% in the same quarter last year, primarily due to the shift from discounted financial assistance to full reimbursement, indicating progress in the company's profitability model.
- Narrowing Operating Losses: The operating loss for Q1 was $1.7 million, with a net loss of $1.8 million; however, management anticipates that losses will gradually decrease as revenue grows, expecting quarterly losses to drop to below $1 million for the remainder of the year.
- VA Channel Order Growth: The company secured a federal supply schedule contract, and while significant orders were not expected in Q1, multiple VA facilities have already placed orders, indicating potential market demand and expansion opportunities in the healthcare sector.
See More
NeurAxis Reports Q1 Revenue of $1.6M
- Revenue Performance: NeurAxis reported a Q1 revenue of $1.6 million for 2026, indicating stable growth potential in the market despite an uncertain overall economic environment.
- Cash Position: As of March 31, 2026, the company had a cash balance of $7.1 million, ensuring operational liquidity and the ability to invest in future opportunities, thereby boosting investor confidence.
- Successful Financing: The company raised an additional $2.1 million through its at-the-market equity offering and warrant exercises in April and May 2026, further enhancing financial flexibility and providing funding support for future expansion.
- Market Outlook: With ongoing optimization of its financial structure and revenue sources, NeurAxis is expected to enhance its competitiveness in the biotechnology sector, attracting more investor interest in its future developments.
See More
NeurAxis Reports 80% Revenue Growth in Q1 2026
- Significant Revenue Growth: NeurAxis reported revenues of $1.6 million for Q1 2026, an 80% increase year-over-year, primarily driven by the effective AMA Category I CPT® code on January 1, 2026, which substantially enhanced payer coverage and boosted sales.
- Gross Margin Improvement: The gross margin increased from 84.4% in Q1 2025 to 86.4% in Q1 2026, primarily due to a higher volume of IB-Stim® devices sold at full price, reflecting the company's strengthened competitive position in the market.
- Reduced Operating Loss: The operating loss for Q1 2026 decreased by 24% to $1.74 million, mainly due to increased gross profit from revenue growth, despite a slight rise in operating expenses driven by sales growth, indicating progress in cost control.
- Improved Cash Position: As of March 31, 2026, NeurAxis had a cash balance of $7.1 million, and subsequently raised $2.1 million through market offerings and warrant exercises in April and May 2026, further enhancing the company's liquidity and financial stability.
See More
NeurAxis Declares Dividend on Series B Preferred Stock
- Dividend Announcement: On April 10, 2026, NeurAxis announced a stock dividend for holders of Series B Preferred Stock, requiring record holders by April 21, 2026, which demonstrates the company's commitment to shareholder returns.
- Dividend Details: Each holder of Series B Preferred Stock will receive common stock based on accrued unpaid dividends at a rate of $2.38, with approximately 510,605 shares expected to be issued, enhancing the company's capital structure flexibility.
- Cash Alternative: For any fractional shares that cannot be issued, NeurAxis will compensate in cash, ensuring all shareholders receive corresponding value, reflecting the company's commitment to shareholder rights.
- Future Outlook: The dividend announcement not only indicates the company's stable financial condition but may also attract more investor interest, further boosting market confidence and potentially enhancing stock performance.
See More
Neuraxis Inc Reports Q4 2025 Earnings with Mixed Results
- Significant Revenue Growth: Neuraxis Inc reported revenues of $968,000 for Q4 2025, a 27% increase from $761,000 in Q4 2024, marking the sixth consecutive quarter of double-digit growth, indicating strong market expansion potential.
- Gross Margin Decline: Despite revenue growth, the gross margin for Q4 decreased to 85.4% from 86.4% in Q4 2024, primarily due to reserves for excess and obsolete inventory, which may impact future profitability.
- Increased Net Loss: The company reported a net loss of $1.7 million for Q4 2025, an 18% increase compared to the same period in 2024, reflecting rising operating expenses of $2.5 million, highlighting challenges in cost control.
- Strong Cash Flow Position: Neuraxis Inc ended 2025 with $5 million in cash on hand and a free cash flow of $2 million, exceeding the quarterly burn rate of $1.5 million, demonstrating robust financial management.
See More
NeurAxis Reports Q4 2025 Financial Results
- Increased Net Loss: NeurAxis reported a net loss of $1.7 million in Q4 2025, an 18% increase from $1.4 million in Q4 2024, primarily due to higher operating losses, indicating challenges in cost management.
- Revenue Performance: The revenue for the quarter stood at $0.97 million; while specific growth figures were not disclosed, the revenue level suggests insufficient competitiveness in the market, potentially impacting future financing capabilities.
- Impact of Operating Loss: The increase in operating losses puts pressure on NeurAxis's financial condition, which may lead to decreased investor confidence in the company's future profitability, thereby affecting stock performance.
- Market Reaction Expectations: Following the earnings report, market reactions to NeurAxis may lean negative, prompting investors to closely monitor how the company addresses ongoing financial challenges and its future strategic adjustments.
See More
